This disclosure provides pharmaceutical adenovirus formulations, in particular, liquid pharmaceutical formulations comprising adenoviruses.

This disclosure provides pharmaceutical adenovirus formulations, in particular, liquid pharmaceutical formulations comprising adenoviruses.

A liquid formulation of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, pharmaceutically acceptable salts thereof, or a combination thereof and the use of the liquid formulation in the treatment of pain, cancer, inflammation, and certain infectious diseases are disclosed.

A liquid formulation of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, pharmaceutically acceptable salts thereof, or a combination thereof and the use of the liquid formulation in the treatment of pain, cancer, inflammation, and certain infectious diseases are disclosed.

The present disclosure provides prolonged release formulation of cannabinoids. The formulation comprises liposomes having a lipid membrane and an intraliposomal aqueous core, wherein said liposome comprises either an entrapped cannabinoid and at least one dispersing agent of said cannabinoid, said dispersing agent being other than a cyclodextrin (CD) compound; or an entrapped cannabinoid, at least a portion of said cannabinoid being entrapped in said lipid membrane, and wherein said lipid membrane comprises a mole ratio between said cannabinoid and said one or more liposome forming lipids in the range of 1 to 10. Also disclosed are methods of preparing and uses of the formulations for prolonged delivery of the cannabinoids and therapeutic treatments making use of same.

The present disclosure provides prolonged release formulation of cannabinoids. The formulation comprises liposomes having a lipid membrane and an intraliposomal aqueous core, wherein said liposome comprises either an entrapped cannabinoid and at least one dispersing agent of said cannabinoid, said dispersing agent being other than a cyclodextrin (CD) compound; or an entrapped cannabinoid, at least a portion of said cannabinoid being entrapped in said lipid membrane, and wherein said lipid membrane comprises a mole ratio between said cannabinoid and said one or more liposome forming lipids in the range of 1 to 10. Also disclosed are methods of preparing and uses of the formulations for prolonged delivery of the cannabinoids and therapeutic treatments making use of same.

The present invention relates to methods and compositions for the treatment of hemangioma, and particularly, but not exclusively, methods and compositions for the treatment of infantile hemangioma. In certain aspects, the methods comprise locally administering an ACE inhibitor or an ATIIR2 antagonist to a subject. In other aspects, the methods comprise systemically administering two or more of an ACE inhibitor, a beta-blocker and an ATIIR2 antagonist. The present invention also relates to compositions that are suitable for local administration and comprise: an ACEi and a beta-blocker; an ACEi and an ATIIR2 antagonist; a beta-blocker and an AT11R2 antagonist; or, an ACEi, a beta-blocker, and an AT11R2 antagonist.

The present invention relates to a composition comprising aspacytarabine (also known as BST-236 and Astarabine®) or a pharmaceutically acceptable salt thereof and an stabilizer and/or solubilizer, wherein the stabilizer and/or solubilizer is selected from at least one water soluble stabilizer and/or solubilizer such as a linear polymer or derivative thereof, an inclusion compound (i.e. cyclodextrin) and combination thereof. The present invention further relates to uses of the composition, particularly for use in the treatment of neoplastic disease.

The present invention relates to a composition comprising aspacytarabine (also known as BST-236 and Astarabine®) or a pharmaceutically acceptable salt thereof and an stabilizer and/or solubilizer, wherein the stabilizer and/or solubilizer is selected from at least one water soluble stabilizer and/or solubilizer such as a linear polymer or derivative thereof, an inclusion compound (i.e. cyclodextrin) and combination thereof. The present invention further relates to uses of the composition, particularly for use in the treatment of neoplastic disease.

A method for preparing a water-soluble curcumin mixture with high bioavailability includes the following steps: A) dissolving curcumin, vitamin C and ascorbyl palmitate in an ethanol aqueous solution, evaporating ethanol under reduced pressure, and vacuum drying to obtain a curcumin-vitamin C-ascorbyl palmitate co-crystal; B) high-speed emulsifying the curcumin-vitamin C-ascorbyl palmitate co-crystal and a wall material colloidal solution under vacuum, sequentially conducting a two-stage wet grinding, a homogenization and a potential adjustment to obtain an emulsified body; and C) subjecting the emulsified body to microencapsulation with a wall material twice and drying to obtain the water-soluble curcumin.